IL2 and lung cancer: Among the first experiments with RT and immunocytokine therapy in lung cancer demonstrated an acceptable safety profile and potential immunogenicity of Selectikine or NHS-IL2 (genetically modified interleukin-2 fused with DNA-targeting antibody NHS76), administered after local irradiation of a single pulmonary lesion in 13 M-NSCLC patients (84).